J&J Positions Tremfya as Stelara Successor With FDA Nod for Ulcerative Colitis

Tremfya’s ulcerative colitis approval on Wednesday comes as Johnson & Johnson’s blockbuster immunotherapy Stelara continues to face growing competition from biosimilars.